Cited by 2,087Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Open access

Miller, Brian C., Sen, Debattama R., Al Abosy, Rose, Bi, Kevin, Virkud, Yamini V., LaFleur, Martin W., Yates, Kathleen B., Lako, Ana, Felt, Kristen, Naik, Girish S., Manos, Michael, Gjini, Evisa, Kuchroo, Juhi R., Ishizuka, Jeffrey J., Collier, Jenna L., Griffin, Gabriel K., Maleri, Seth, Comstock, Dawn E., Weiss, Sarah A., Brown, Flavian D., Panda, Arpit, Zimmer, Margaret D., Manguso, Robert T., Hodi, F. Stephen, Rodig, Scott J., Sharpe, Arlene H., Haining, W. Nicholas·2019·Nature Immunology

DOI 10.1038/s41590-019-0312-6PMC PMC6673650

Open this paper in CoChat — free account

Abstract

T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fully understood. Here we show that such therapy acts on a specific subpopulation of exhausted CD8+ tumor-infiltrating lymphocytes (TILs). Dysfunctional CD8+ TILs possess canonical epigenetic and transcriptional features of exhaustion that mirror those seen in chronic viral infection. Exhausted CD8+ TILs include a subpopulation of 'progenitor exhausted' cells that retain polyfunctionality, persist long term and differentiate into 'terminally exhausted' TILs. Consequently, progenitor exhausted CD8+ TILs are better able to control tumor growth than are terminally exhausted T cells. Progenitor exhausted TILs can respond to anti-PD-1 therapy, but terminally exhausted TILs cannot. Patients with melanoma who have a higher percentage of progenitor exhausted cells experience a longer duration of response to checkpoint-blockade therapy. Thus, approaches to expand the population of progenitor exhausted CD8+ T cells might be an important component of improving the response to checkpoint blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41590-019-0312-6

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Spatial reconstruction of single-cell gene expression data
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F., & Regev, A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3192 · Cited by 7,055
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T cell exhaustion
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Self-citation
Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes
Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Rácz, P., Tenner‐Racz, K., Dalesandro, M. R., Scallon, B. J., et al. (1999) · Science · doi:10.1126/science.283.5403.857 · Cited by 2,167
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Self-citation
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072

Show all 53 references

Sorted by citations

Items 101–200 of 1,002

Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity
Vignali, P. D. A., DePeaux, K., Watson, M. J., Ye, C., Ford, B. R., Lontos, K., McGaa, N. K., Scharping, N. E., Menk, A. V., Robson, S. C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01379-9 · Cited by 269
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer
Freed-Pastor, W. A., Lambert, L. J., Ely, Z. A., Pattada, N. B., Bhutkar, A., Eng, G., Mercer, K. L., Garcia, A. P., Lin, L., Rideout, W. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.007 · Cited by 273
Heterogenous Populations of Tissue-Resident CD8+ T Cells Are Generated in Response to Infection and Malignancy
Milner, J. J., Toma, C., He, Z., Kurd, N. S., Nguyen, Q., McDonald, B., Quezada, L. K., Widjaja, C. E., Witherden, D. A., Crowl, J. T., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.007 · Cited by 278
Promises and challenges of adoptive T-cell therapies for solid tumours
Morotti, M., Albukhari, A., Alsaadi, A., Artibani, M., Brenton, J. D., Curbishley, S. M., Dong, T., Dustin, M. L., Hu, Z., McGranahan, N., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01353-6 · Cited by 278
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy
Asrir, A., Tardiveau, C., Coudert, J., Laffont, R., Blanchard, L., Bellard, E., Veerman, K. M., Bettini, S., Lafouresse, F., Vina, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.002 · Cited by 286
MYB orchestrates T cell exhaustion and response to checkpoint inhibition
Tsui, C., Kretschmer, L., Rapelius, S., Gabriel, S. S., Chisanga, D., Knöpper, K., Utzschneider, D. T., Nüssing, S., Liao, Y., Mason, T., et al. (2022) · Nature · doi:10.1038/s41586-022-05105-1 · Cited by 264
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Au, L., Hatipoglu, E., de Massy, M. R., Litchfield, K., Beattie, G., Rowan, A., Schnidrig, D., Thompson, R. H., Byrne, F., Horswell, S. D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.001 · Cited by 262
Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation
Abdel-Hakeem, M. S., Manne, S., Beltra, J., Stelekati, E., Chen, Z., Nzingha, K., Ali, M.-A., Johnson, J. L., Giles, J. R., Mathew, D., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00975-5 · Cited by 252
Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans
Yates, K. B., Tonnerre, P., Martin, G. E., Gerdemann, U., Abosy, R. A., Comstock, D. E., Weiss, S. A., Wolski, D., Tully, D. C., Chung, R. T., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00979-1 · Cited by 257
Self-citation
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
Lee, A., Sun, L., Mochizuki, A. Y., Reynoso, J. G., Orpilla, J. R., Chow, F. E., Kienzler, J. C., Everson, R. G., Nathanson, D. A., Bensinger, S. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26940-2 · Cited by 262
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity
LaFleur, M. W., Nguyen, T. H., Coxe, M. A., Miller, B. C., Yates, K. B., Gillis, J. E., Sen, D. R., Gaudiano, E. F., Abosy, R. A., Freeman, G. J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0480-4 · Cited by 257
Self-citation
TCF1 in T cell immunity: a broadened frontier
Zhao, X., Shan, Q., & Xue, H. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00563-6 · Cited by 252
Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity
Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology · doi:10.1038/s41590-021-00949-7 · Cited by 237
Self-citation
Androgen conspires with the CD8 + T cell exhaustion program and contributes to sex bias in cancer
Kwon, H., Schafer, J. M., Song, N., Kaneko, S., Li, A., Xiao, T., Ma, A., Allen, C., Das, K., Zhou, L., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq2630 · Cited by 254
Cellular networks controlling T cell persistence in adoptive cell therapy
Chan, J. D., Lai, J., Slaney, C. Y., Kallies, A., Beavis, P. A., & Darcy, P. K. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00539-6 · Cited by 253
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
Arrieta, V. A., Dmello, C., McGrail, D. J., Brat, D. J., Lee-Chang, C., Heimberger, A. B., Chand, D. S., Stupp, R., & Sonabend, A. M. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163447 · Cited by 249
Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy
Francis, D. M., Manspeaker, M. P., Schudel, A., Sestito, L. F., O’Melia, M. J., Kissick, H. T., Pollack, B. P., Waller, E. K., & Thomas, S. N. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay3575 · Cited by 240
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
Mathew, D., Marmarelis, M. E., Foley, C., Bauml, J. M., Ye, D., Ghinnagow, R., Ngiow, S. F., Klapholz, M., Jun, S., Zhang, Z., et al. (2024) · Science · doi:10.1126/science.adf1329 · Cited by 252
Developing neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 241
CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?
Hoyt-Miggelbrink, A. M., Jackson, J. D., Lorrey, S., Srinivasan, E. S., Polania, J. W., Wilkinson, D. S., & Fecci, P. E. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0206 · Cited by 258
The Contribution of Epigenetics to Cancer Immunotherapy
Villanueva, L., Álvarez‐Errico, D., & Esteller, M. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.002 · Cited by 238
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer
Virassamy, B., Caramia, F., Savas, P. S., Sant, S. A., Wang, J., Christo, S. N., Byrne, A., Clarke, K. A., Brown, E., Teo, Z. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.004 · Cited by 247
Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2–reactive CD8 + T cells
Kusnadi, A., Ramírez-Suástegui, C., Fajardo, V., Chee, S., Meckiff, B. J., Simon, H. A., Pelosi, E., Seumois, G., Ay, F., Vijayanand, P., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe4782 · Cited by 237
Memory T cell, exhaustion, and tumor immunity
Ando, M., Ito, M., Srirat, T., Kondo, T., & Yoshimura, A. (2019) · Immunological Medicine · doi:10.1080/25785826.2019.1698261 · Cited by 233
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Chiang, E. Y., & Mellman, I. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004711 · Cited by 235
‘Stem-like’ precursors are the fount to sustain persistent CD8+ T cell responses
Zehn, D., Thimme, R., Lugli, E., de Almeida, G. P., & Oxenius, A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01219-w · Cited by 232
FOXO1 is a master regulator of memory programming in CAR T cells
Doan, A. E., Mueller, K. P., Chen, A. Y., Rouin, G. T., Chen, Y., Dániel, B., Lattin, J., Markovska, M., Mozarsky, B., Arias-Umana, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07300-8 · Cited by 241
Divergent clonal differentiation trajectories of T cell exhaustion
Dániel, B., Yost, K. E., Hsiung, S., Sándor, K., Xia, Y., Qi, Y., Hiam-Galvez, K. J., Black, M., Raposo, C. J., Shi, Q., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01337-5 · Cited by 241
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Schnell, A., Bod, L., Madi, A., & Kuchroo, V. K. (2020) · Cell Research · doi:10.1038/s41422-020-0277-x · Cited by 234
Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
Giraud, J., Chalopin, D., Blanc, J., & Saleh, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655697 · Cited by 226
Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade
Jadhav, R. R., Im, S. J., Hu, B., Hashimoto, M., Li, P., Lin, J., Leonard, W. J., Greenleaf, W. J., Ahmed, R., & Goronzy, J. J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903520116 · Cited by 224
Memory CD8+ T cell responses to cancer
Han, J., Khatwani, N., Searles, T. G., Turk, M. J., & Angeles, C. V. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101435 · Cited by 236
Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19
Wilk, A. J., Lee, M. J., Wei, B., Parks, B. E., Pi, R., Martínez-Colón, G. J., Ranganath, T., Zhao, N. Q., Taylor, S., Becker, W. R., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210582 · Cited by 214
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · 癌症：英文版 · doi:10.1002/cac2.12178 · Cited by 221
Stem-like exhausted and memory CD8+ T cells in cancer
Gebhardt, T., Park, S. L., & Parish, I. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00615-0 · Cited by 234
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Memon, D., Schoenfeld, A. J., Ye, D., Fromm, G. J., Rizvi, H. A., Zhang, X., Keddar, M. R., Mathew, D., Yoo, K. J., Qiu, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.013 · Cited by 230
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells
Lacher, S. B., Dörr, J., de Almeida, G. P., Hönninger, J., Bayerl, F., Hirschberger, A., Pedde, A., Meiser, P., Ramsauer, L., Rudolph, T. J., et al. (2024) · Nature · doi:10.1038/s41586-024-07254-x · Cited by 222
T cell factor 1: A master regulator of the T cell response in disease
Escobar, G., Mangani, D., & Anderson, A. C. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb9726 · Cited by 211
Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy
Chen, G. M., Chen, C., Das, R. K., Gao, P., Chen, C., Bandyopadhyay, S., Ding, Y., Uzun, Y., Yu, W., Zhu, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1677 · Cited by 218
High endothelial venules (HEVs) in immunity, inflammation and cancer
Blanchard, L., & Girard, J. (2021) · Angiogenesis · doi:10.1007/s10456-021-09792-8 · Cited by 231
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer
Chen, Y., Wang, D., Li, Y., Lu, Q., Si, W., Bo, Y., Chen, X., Ye, Z., Fan, H., Liu, B., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.009 · Cited by 229
Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor
Zhang, J., Li, J., Hou, Y., Lin, Y., Zhao, H., Shi, Y., Chen, K., Nian, C., Tang, J., Pan, L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.04.023 · Cited by 214
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers
Hanada, K.-I., Zhao, C., Gil-Hoyos, R., Gartner, J. J., Chow-Parmer, C., Lowery, F. J., Krishna, S., Prickett, T. D., Kivitz, S., Parkhurst, M. R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.012 · Cited by 200
A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity
Meiser, P., Knolle, M. A., Hirschberger, A., de Almeida, G. P., Bayerl, F., Lacher, S. B., Pedde, A., Flommersfeld, S., Hönninger, J., Stark, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.008 · Cited by 208
Therapeutic depletion of CCR8 + tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
Van Damme, H., Dombrecht, B., Kiss, M., Roose, H., Allen, E., Van Overmeire, E., Kancheva, D., Martens, L., Murgaski, A., Bardet, P. M. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001749 · Cited by 205
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
Kirtane, K., Elmariah, H., Chung, C. H., & Abate‐Daga, D. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002723 · Cited by 205
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
Baharom, F., Ramirez-Valdez, R. A., Tobin, K. K. S., Yamane, H., Dutertre, C., Khalilnezhad, A., Reynoso, G. V., Coble, V. L., Lynn, G. M., Mulè, M. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-00810-3 · Cited by 205
Y chromosome loss in cancer drives growth by evasion of adaptive immunity
Abdel-Hafiz, H. A., Schafer, J. M., Chen, X., Xiao, T., Gauntner, T. D., Li, Z., & Theodorescu, D. (2023) · Nature · doi:10.1038/s41586-023-06234-x · Cited by 204
BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells
Yao, C., Lou, G., Sun, H., Zhu, Z., Sun, Y. E., Chen, Z., Chauss, D., Moseman, E. A., Cheng, J., D’Antonio, M. A., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00868-7 · Cited by 196
The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function
Wenes, M., Jaccard, A., Wyss, T., Maldonado‐Pérez, N., Teoh, S. T., Lepez, A., Renaud, F., Franco, F., Waridel, P., Maroun, C. Y., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.03.013 · Cited by 215
Landscape of helper and regulatory antitumour CD4+ T cells in melanoma
Oliveira, G., Stromhaug, K., Cieri, N., Iorgulescu, J. B., Klaeger, S., Wolff, J. O., Rachimi, S., Chea, V. A., Krause, K., Freeman, S. S., et al. (2022) · Nature · doi:10.1038/s41586-022-04682-5 · Cited by 205
Self-citation
Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Egen, J. G., Ouyang, W., & Wu, L. C. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.010 · Cited by 198
Central memory CD8+ T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation
Ferreira, D. P., da Silva, J. G., Wyss, T., Marraco, S. A. F., Scarpellino, L., Charmoy, M., Maas, R. R., Siddiqui, I., Tang, L., Joyce, J. A., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.09.005 · Cited by 200
Chromatin accessibility profiling methods
Minnoye, L., Marinov, G. K., Krausgruber, T., Pan, L., Marand, A. P., Secchia, S., Greenleaf, W. J., Furlong, E. E. M., Zhao, K., Schmitz, R. J., et al. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-020-00008-9 · Cited by 206
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Baumgartner, C. K., Ebrahimi-Nik, H., Iracheta‐Vellve, A., Hamel, K. M., Olander, K. E., Davis, T. G. R., McGuire, K. A., Halvorsen, G. T., Avila, O. I., Patel, C. H., et al. (2023) · Nature · doi:10.1038/s41586-023-06575-7 · Cited by 204
Self-citation
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
Wan, C., Keany, M. P., Dong, H., Al-Alem, L., Pandya, U. M., Lazo, S., Boehnke, K., Lynch, K. N., Xu, R., Zarrella, D. T., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1674 · Cited by 201
Opposing Roles of Type I Interferons in Cancer Immunity
Boukhaled, G. M., Harding, S. M., & Brooks, D. G. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-031920-093932 · Cited by 208
Emerging concepts in PD-1 checkpoint biology
Pauken, K. E., Torchia, J. A., Chaudhri, A., Sharpe, A. H., & Freeman, G. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101480 · Cited by 203
Self-citation
Age-associated remodeling of T cell immunity and metabolism
Han, S., Georgiev, P., Ringel, A. E., Sharpe, A. H., & Haigis, M. C. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.005 · Cited by 200
Self-citation
Tissue-Resident Memory T Cells in Cancer Immunosurveillance
Park, S. L., Gebhardt, T., & Mackay, L. K. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.06.002 · Cited by 197
Transforming growth factor-β-regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection
Gabriel, S. S., Tsui, C., Chisanga, D., Weber, F., Llano-León, M., Gubser, P. M., Bartholin, L., Souza-Fonseca-Guimarães, F., Huntington, N. D., Shi, W., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.007 · Cited by 200
Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Kim, S. P., Vale, N. R., Zacharakis, N., Krishna, S., Yu, Z., Gasmi, B., Gartner, J. J., Sindiri, S., Malekzadeh, P., Deniger, D. C., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0040 · Cited by 195
Targeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala‐Dilke, K., & Bergers, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 216
Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells
Drijvers, J. M., Gillis, J. E., Muijlwijk, T., Nguyen, T. H., Gaudiano, E. F., Harris, I. S., LaFleur, M. W., Ringel, A. E., Yao, C.-H., Kurmi, K., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0384 · Cited by 191
Self-citation
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.008 · Cited by 191
Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity
Yang, C., Jin, J., Yang, Y., Sun, H., Wu, L., Shen, M., Hong, X., Li, W., Lu, L., Cao, D., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.012 · Cited by 195
Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism
Peralta, R. M., Xie, B., Lontos, K., Nieves-Rosado, H. M., Spahr, K., Joshi, S. K., Ford, B. R., Quann, K., Frisch, A. T., Dean, V. G., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01999-3 · Cited by 222
Transcriptional mediators of treatment resistance in lethal prostate cancer
He, M. X., Cuoco, M. S., Crowdis, J. P., Bosma-Moody, A., Zhang, Z., Bi, K., Kanodia, A., Su, M.-J., Ku, S., Garcia, M. M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01244-6 · Cited by 186
Self-citation
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00503-z · Cited by 190
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma
Liu, Z., Zhang, Y., Ma, N., Yang, Y., Ma, Y., Wang, F., Wang, Y., Wei, J., Chen, H., Tartarone, A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.011 · Cited by 197
CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17
Corgnac, S., Malenica, I., Mezquita, L., Auclin, É., Voilin, E., Kacher, J., Halse, H. M., Grynszpan, L., Signolle, N., Dayris, T., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100127 · Cited by 191
BATF regulates progenitor to cytolytic effector CD8+ T cell transition during chronic viral infection
Chen, Y., Zander, R., Wu, X., Schauder, D., Kasmani, M. Y., Shen, J., Zheng, S., Burns, R., Taparowsky, E. J., & Cui, W. (2021) · Nature Immunology · doi:10.1038/s41590-021-00965-7 · Cited by 183
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
Westcott, P. M. K., Sacks, N. J., Schenkel, J. M., Ely, Z. A., Smith, O. C. G., Hauck, H., Jaeger, A. M., Zhang, D., Backlund, C. M., Beytagh, M. C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00247-z · Cited by 187
Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles
Li, J., Luo, Y., Zeng, Z., Cui, D. M., Huang, J., Xu, C., Li, L., Pu, K., & Zhang, R. (2022) · Nature Communications · doi:10.1038/s41467-022-31551-6 · Cited by 184
Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy
Chen, J. H., Nieman, L. T., Spurrell, M., Jorgji, V., Elmelech, L., Richieri, P. M., Xu, K. H., Madhu, R., Parikh, M., Zamora, I., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01792-2 · Cited by 204
Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19
Unterman, A., Sumida, T. S., Nouri, N., Yan, X., Zhao, A., Gasque, V., Schupp, J. C., Asashima, H., Liu, Y., Cosme, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27716-4 · Cited by 181
Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer
Zhou, P., Shi, H., Huang, H., Sun, X., Yuan, S., Chapman, N. M., Connelly, J. P., Lim, S. A., Saravia, J., Anil, K. C., et al. (2023) · Nature · doi:10.1038/s41586-023-06733-x · Cited by 190
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 176
Contribution of resident and circulating precursors to tumor-infiltrating CD8 + T cell populations in lung cancer
Gueguen, P., Metoikidou, C., Dupic, T., Lawand, M., Goudot, C., Baulande, S., Lameiras, S., Lantz, O. J., Girard, N., Seguin‐Givelet, A., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd5778 · Cited by 181
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
Lee, J. B., Kim, H. R., & Ha, S. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 175
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop
Hua, Y., Vella, G., Rambow, F., Allen, E., Antoranz, A., Duhamel, M., Takeda, A., Jalkanen, S., Junius, S., Smeets, A., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.002 · Cited by 176
Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice
Chiu, D. K., Yuen, V. W., Cheu, J. W., Wei, L. L., Ting, V., Fehlings, M., Sumatoh, H., Nardin, A., Newell, E. W., Ng, I. O., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.074 · Cited by 171
Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment
Qiao, G., Chen, M., Mohammadpour, H., MacDonald, C. R., Bucsek, M. J., Hylander, B. L., Barbi, J. J., & Repasky, E. A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0445 · Cited by 181
Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses
Wei, J., Montalvo-Ortiz, W., Yu, L., Krasco, A., Ebstein, S., Cortez, C. A., Lowy, I., Murphy, A. J., Sleeman, M. A., & Skokos, D. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg0117 · Cited by 174
Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection
Hensel, N., Gu, Z., Sagar, Wieland, D., Jechow, K., Kemming, J. S., Llewellyn‐Lacey, S., Emma Gostick, D., Sogukpinar, O., Emmerich, F., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00817-w · Cited by 159
Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches
Fisicaro, P., Barili, V., Rossi, M., Montali, I., Vecchi, A. L., Acerbi, G., Laccabue, D., Zecca, A., Penna, A., Missale, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00849 · Cited by 173
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
Pai, J. A., Hellmann, M. D., Sauter, J. L., Mattar, M. S., Rizvi, H. A., Woo, H. J., Shah, N., Nguyen, E. M., Uddin, F. Z., Quintanal-Villalonga, À., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.009 · Cited by 177
CD8+ T cell exhaustion and cancer immunotherapy
Wang, Q., Qin, Y., & Li, B. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216043 · Cited by 155
Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target
Lou, H., Ling, G. S., & Cao, X. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102861 · Cited by 175
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity
Elewaut, A., Estivill, G., Bayerl, F., Castillon, L., Novatchkova, M., Pottendorfer, E., Hoffmann-Haas, L., Schönlein, M., Nguyễn, T. C. B., Lauss, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08257-4 · Cited by 167
Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer
Kim, K.-S., Park, S., Park, S. Y., Kim, G., Park, S. M., Cho, J.-W., Kim, D., Park, Y. M., Koh, Y. W., Kim, H. R., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00722-9 · Cited by 164
Antigen Dominance Hierarchies Shape TCF1+ Progenitor CD8 T Cell Phenotypes in Tumors
Burger, M. L., Cruz, A. M., Crossland, G. E., Gaglia, G., Ritch, C. C., Blatt, S. E., Bhutkar, A. J., Canner, D. A., Kienka, T., Tavana, S. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.020 · Cited by 158
Self-citation
The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation
Martin, T. D., Patel, R. S., Cook, D. R., Choi, M. Y., Patil, A., Liang, A. C. T., Li, M. Z., Haigis, K. M., & Elledge, S. J. (2021) · Science · doi:10.1126/science.abg5784 · Cited by 154
Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Wu, M., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1077 · Cited by 158
Self-citation
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., Parisi, G., Zaretsky, J. M., Garcia-Diaz, A., Puig-Saus, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1409 · Cited by 146
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function
Veatch, J. R., Lee, S. M., Shasha, C., Singhi, N., Szeto, J. L., Moshiri, A. S., Kim, T. S., Smythe, K. S., Kong, P., Fitzgibbon, M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.006 · Cited by 159
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
Ramachandran, M., Vaccaro, A., van de Walle, T., Georganaki, M., Lugano, R., Vemuri, K., Kourougkiaouri, D., Vazaios, K., Hedlund, M., Tsaridou, G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.010 · Cited by 160
Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy
Celis-Gutierrez, J., Blattmann, P., Zhai, Y., Jarmuzynski, N., Ruminski, K., Grégoire, C., Ounoughene, Y., Fiore, F., Aebersold, R., Roncagalli, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.041 · Cited by 154
Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells
Liikanen, I., Lauhan, C. R., Quon, S., Omilusik, K. D., Phan, A. T., Bartrolí, L. B., Ferry, A., Goulding, J., Chen, J., Scott-Browne, J. P., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143729 · Cited by 160

Authors: Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., Manos, M., Gjini, E., Kuchroo, J. R., Ishizuka, J. J., Collier, J. L., Griffin, G. K., Maleri, S., Comstock, D. E., Weiss, S. A., Brown, F. D., Panda, A., Zimmer, M. D., Manguso, R. T., Hodi, F. S., Rodig, S. J., Sharpe, A. H., & Haining, W. N.
Affiliations: Broad Institute (US)
Massachusetts General Hospital (US)
Dana-Farber Cancer Institute (US)
Brigham and Women's Hospital (US)
Corresponding author: Haining, W. Nicholas
ORCID: Miller, Brian C.
Sen, Debattama R.
Al Abosy, Rose
Bi, Kevin
Virkud, Yamini V.
LaFleur, Martin W.
Yates, Kathleen B.
Lako, Ana
Felt, Kristen
Naik, Girish S.
Manos, Michael
Gjini, Evisa
Kuchroo, Juhi R.
Ishizuka, Jeffrey J.
Collier, Jenna L.
Griffin, Gabriel K.
Comstock, Dawn E.
Weiss, Sarah A.
Zimmer, Margaret D.
Manguso, Robert T.
Hodi, F. Stephen
Rodig, Scott J.
Sharpe, Arlene H.
Haining, W. Nicholas
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2019-02-18
Volume: 20
Issue: 3
Pages: 326-336
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/s41590-019-0312-6
PMC: PMC6673650
OpenAlex: W2913558101
Cited by: 2,087
References: 53
Citations by year: 2026: 319 · 2025: 334 · 2024: 358 · 2023: 300 · 2022: 276 · 2021: 269 · 2020: 176 · 2019: 55
FWCI: 81.19
Type: journal article
Language: en
Update notices: correction (2019-10-03)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (KL2TR002542)
National Heart, Lung, and Blood Institute (T32HL007627)
National Cancer Institute (T32CA207021, T32CA009172)
National Institute of General Medical Sciences (T32GM007753)
National Institute of Allergy and Infectious Diseases (R01AI115712, K23AI130408, U19AI133524, P01AI056299)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: T cell exhaustion, CD8+ T cells, PD-1, anti-PD-1 therapy, immune checkpoint blockade, tumor-infiltrating lymphocytes, melanoma, T cell polyfunctionality, chronic viral infection, tumor control
MeSH terms: Animals, Female, Humans, Lymphocytic Choriomeningitis, Lymphocytic choriomeningitis virus, Melanoma, Experimental, Mice, Inbred C57BL, Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Antibodies, Blocking, Mice, Congenic, Cell Line, Tumor, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks